Trevi jumps as chronic cough therapy succeeds mid-stage trial

Shares of therapy developer Trevi Therapeutics TRVI.O rise 21.9% to $5.24 premarket

Co says its therapy, Haduvio, met the main goal in a mid-stage trial testing in patients with a type of chronic cough

Says therapy showed statistically significant reduction in 24-hour cough frequency

Currently, there are no approved treatments in the U.S. for coughing bouts that don't have no identifiable cause or those that persist despite treatment of underlying conditions

GSK GSK.L has a chronic cough treatment in development, and Merck has an experimental drug for the disease which faced two FDA rejections in the past

Up to last close, TRVI up 45.8% in the last 12 months